Strongbridge Biopharma
Dublin
About Strongbridge Biopharma
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $196.5M
- Funding stage: M&A
- Last round: Debt Financing (Jan 2020)
- Ticker: nasdaq:SBBP
- Website: strongbridgebio.com
- Phone: +111610254920
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/strongbridge-biopharma-158085 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.